NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.77 -0.39 (-3.49 %) (As of 01/22/2019 06:00 AM ET)Previous Close$11.16Today's Range$10.70 - $11.3252-Week Range$8.59 - $17.98Volume411,447 shsAverage Volume442,636 shsMarket Capitalization$675.62 millionP/E RatioN/ADividend YieldN/ABeta2.49 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; collaboration with Alexion Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases; a license agreement with City of Hope; and a licensing and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of medicines in the areas of cardio-metabolic disease, neurodegeneration, and pain. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts. Receive DRNA News and Ratings via Email Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRNA Previous Symbol CUSIPN/A Webwww.dicerna.com Phone617-621-8097Debt Debt-to-Equity RatioN/A Current Ratio6.30 Quick Ratio6.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.28 million Price / Sales296.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book5.49Profitability EPS (Most Recent Fiscal Year)($3.66) Net Income$-60,040,000.00 Net Margins-1,418.01% Return on Equity-63.24% Return on Assets-51.85%Miscellaneous Employees44 Outstanding Shares62,730,000Market Cap$675.62 million OptionableOptionable Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions What is Dicerna Pharmaceuticals' stock symbol? Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA." How were Dicerna Pharmaceuticals' earnings last quarter? Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) issued its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.11. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.67 million. Dicerna Pharmaceuticals had a negative return on equity of 63.24% and a negative net margin of 1,418.01%. View Dicerna Pharmaceuticals' Earnings History. When is Dicerna Pharmaceuticals' next earnings date? Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Dicerna Pharmaceuticals. What price target have analysts set for DRNA? 9 equities research analysts have issued 12 month target prices for Dicerna Pharmaceuticals' stock. Their forecasts range from $14.50 to $30.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $21.3125 in the next twelve months. This suggests a possible upside of 97.9% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals. What is the consensus analysts' recommendation for Dicerna Pharmaceuticals? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals. Has Dicerna Pharmaceuticals been receiving favorable news coverage? Media coverage about DRNA stock has trended very positive this week, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a news impact score of 3.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Are investors shorting Dicerna Pharmaceuticals? Dicerna Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 5,979,289 shares, an increase of 75.9% from the December 14th total of 3,399,119 shares. Based on an average trading volume of 929,548 shares, the short-interest ratio is currently 6.4 days. Approximately 13.2% of the company's shares are sold short. View Dicerna Pharmaceuticals' Current Options Chain. Who are some of Dicerna Pharmaceuticals' key competitors? Some companies that are related to Dicerna Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN) and Innoviva (INVA). Who are Dicerna Pharmaceuticals' key executives? Dicerna Pharmaceuticals' management team includes the folowing people: Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 49)Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 53)Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 65)Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory BoardProf. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 71) How do I buy shares of Dicerna Pharmaceuticals? Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Dicerna Pharmaceuticals' stock price today? One share of DRNA stock can currently be purchased for approximately $10.77. How big of a company is Dicerna Pharmaceuticals? Dicerna Pharmaceuticals has a market capitalization of $675.62 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe. What is Dicerna Pharmaceuticals' official website? The official website for Dicerna Pharmaceuticals is http://www.dicerna.com. How can I contact Dicerna Pharmaceuticals? Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected] MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 252 (Vote Outperform)Underperform Votes: 189 (Vote Underperform)Total Votes: 441MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2019 by MarketBeat.com StaffFeatured Article: What is the quiet period?